Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort studyResearch in context

Summary: Background: The pivotal phase 3 efficacy clinical trial has demonstrated that a two-dose regimen of dNS1-RBD (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) is well-tolerated and provides wide protection against SARS-CoV-2 infection. However, the effectiveness of a single-d...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hongfei Mi, Qi Chen, Hongyan Lin, Tingjuan He, Ruixin Zhang, Shuhao Ren, Lingling Liu, Jing Wang, Hua Huang, Meixia Wang, Zhinan Guo, Chenghao Su
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-01-01
Edice:	EClinicalMedicine
Témata:	Effectiveness Intranasal spray COVID-19 vaccine dNS1-RBD Single-dose regimen SARS-CoV-2
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589537023005515
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!